ADAM17 as a promising therapeutic target: from structural basis to inhibitor discovery in human diseases
Open Access
- 19 September 2025
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 16, 1640090
Abstract
A disintegrin and metalloproteinase 17 (ADAM17) is a transmembrane protease that regulates diverse physiological processes by shedding membrane-bound proteins, including cytokines, their receptors, and adhesion molecules. A mounting body of evidence has emerged linking ADAM17 to the pathogenesis of various diseases, including inflammation, cancer, cardiovascular and neurodegenerative diseases, highlighting its potential as a therapeutic target. This review offers a comprehensive overview of the molecular structure and biological functions of ADAM17, emphasizing its role in human diseases and therapeutic strategies that target ADAM17 activity. Recent advances in the development of ADAM17-targeting agents, including small-molecule inhibitors, monoclonal antibodies, and endogenous regulatory proteins, are discussed with a focus on the structural basis of their activity, with the aim of informing and guiding future drug discovery efforts.Keywords
This publication has 145 references indexed in Scilit:
- Identification of circulating T‐cell immunoglobulin and mucin domain 4 as a potential biomarker for coronary heart diseaseMedcomm, 2023
- Chemotherapy‐induced release of ADAM17 bearing EV as a potential resistance mechanism in ovarian cancerJournal of Extracellular Vesicles, 2023
- Meprin and ADAM proteases as triggers of systemic inflammation in sepsisFEBS Letters, 2021
- Regulation of osteoarthritis development by ADAM17/Tace in articular cartilageJournal of Bone and Mineral Metabolism, 2021
- Contribution of ADAM17 and related ADAMs in cardiovascular diseasesCellular and Molecular Life Sciences, 2021
- The Distinct Role of ADAM17 in APP Proteolysis and Microglial Activation Related to Alzheimer’s DiseaseCellular and Molecular Neurobiology, 2015
- Synthesis of [3H], [13C3, 15N], and [14C]SCH 900567: an inhibitor of TNF‐α (tumor necrosis factor alpha) converting enzyme (TACE)Journal of Labelled Compounds and Radiopharmaceuticals, 2014
- ADAM17 is overexpressed in non-small cell lung cancer and its expression correlates with poor patient survivalTumor Biology, 2013
- ADAM17-overexpressing breast cancer cells selectively targeted by antibody–toxin conjugatesCancer Immunology, Immunotherapy, 2012
- Prognostic value of ADAM17 in human gastric cancerMedical Oncology, 2011